Novo Holdings

Activity in this selectionlife-sciences-at-goldman-sachs-alternatives-5af2f92b

By stage

Series C+2

Series B1

Biotech3

United States2

Denmark1

3 in this selection

Jul 22

Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout

$130MSeries B

Role not disclosed

Apr 15

Develops highly targeted, small molecule medicines for cancer and rare diseases

$108MSeries C

Role not disclosed

Apr 14

Develops first- and best-in-class antibody-drug conjugates (ADCs) for cancer treatment

$75MSeries C

Role not disclosed